Company news
Marvel Biosciences Corp news in 2021
Marvel Biosciences Corp's news releases, calls and decks from 2021, newest first.
Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204
December 16, 2021
Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound
December 8, 2021
Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
December 3, 2021
Marvel Biosciences to Host Investor Webinar
November 29, 2021
Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash
November 23, 2021
Marvel Biosciences Appoints Scientific Advisory Board
November 9, 2021
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
October 27, 2021
Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
October 15, 2021
Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer's Drug Discovery
September 17, 2021
Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases
August 5, 2021
Marvel Biosciences Corp. Retains Virtus Advisory Group to Provide Corporate Communications Services
August 3, 2021
Marvel Biosciences Corp. to Commence cGMP Manufacturing of Its Lead Asset MB-204
July 21, 2021
Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.
July 8, 2021